awmsg logo



tapentadol (Palexia® SR)


Reference No. 651

Publication date:
12/01/2012


Appraisal information

tapentadol (Palexia® SR) prolonged-release tablet


Company: Grunenthal Ltd
BNF category: Central nervous system
NMG meeting date: 05/10/2011
AWMSG meeting date: 09/11/2011
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 1511
Ministerial ratification: 09/01/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Tapentadol prolonged release (Palexia® SR) is recommended as an option for restricted use within NHS Wales, only in the following subpopulation within its licensed indication: Patients with severe chronic pain, in whom morphine sulphate modified release has failed to provide adequate pain control or is not tolerated. Tapentadol prolonged release (Palexia® SR) is not recommended for the management of severe chronic pain in adults, which can be adequately managed only with opioid analgesics, outside of the subpopulation described above. AWMSG is of the opinion that tapentadol prolonged release (Palexia® SR) should be initially prescribed by a specialist*. Prescribing may be continued in primary care with appropriate communication and specialist input. *Specialist implies specialist team or GP with special interest (GPwSI) with appropriate accreditation from the specialist faculty.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download